

mRNA vaccine-elicited antibodies to SARS-CoV-2 and c

Nature

592, 616-622

DOI: [10.1038/s41586-021-03324-6](https://doi.org/10.1038/s41586-021-03324-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?. International Journal of Biological Sciences, 2021, 17, 1476-1485.	2.6	23
2	Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers. Journal of Medical Biochemistry, 2021, 40, 327-334.	0.7	21
3	AutoVEM2: A flexible automated tool to analyze candidate key mutations and epidemic trends for virus. Computational and Structural Biotechnology Journal, 2021, 19, 5029-5038.	1.9	4
4	Impact of New Variants on SAR-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions. SSRN Electronic Journal, 0, , .	0.4	3
5	Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?. Journal of Korean Medical Science, 2021, 36, e124.	1.1	64
11	Computational optimization of angiotensin-converting enzyme 2 for SARS-CoV-2 Spike molecular recognition. Computational and Structural Biotechnology Journal, 2021, 19, 3006-3014.	1.9	9
12	Will the large-scale vaccination succeed in containing the COVID-19 pandemic and how soon?. Quantitative Biology, 2021, 9, 304-316.	0.3	3
13	The evolutionary dynamics of endemic human coronaviruses. Virus Evolution, 2021, 7, veab020.	2.2	40
14	Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces. International Journal of Biological Sciences, 2021, 17, 1461-1468.	2.6	37
15	Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design. Computational and Structural Biotechnology Journal, 2021, 19, 1661-1671.	1.9	7
17	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. Comparative Medicine, 2021, 71, 342-358.	0.4	3
18	Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study. Indian Journal of Medical Research, 2021, 153, 671.	0.4	12
19	B Cell Receptor Repertoire Kinetics after SARS-CoV-2 Infection and Vaccination. SSRN Electronic Journal, 0, , .	0.4	0
20	Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients. Emerging Microbes and Infections, 2021, 10, 1097-1111.	3.0	25
27	Molecular Epidemiology Surveillance of SARS-CoV-2: Mutations and Genetic Diversity One Year after Emerging. Pathogens, 2021, 10, 184.	1.2	29
31	The challenge of emerging SARS-CoV-2 mutants to vaccine development. Journal of Genetics and Genomics, 2021, 48, 102-106.	1.7	19
36	Viral Vectors for COVID-19 Vaccine Development. Viruses, 2021, 13, 317.	1.5	65
38	Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Science Immunology, 2021, 6, .	5.6	153

#	ARTICLE	IF	CITATIONS
44	Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. <i>Nature</i> , 2021, 593, 142-146.	13.7	574
47	mRNA SARS-CoV-2 Immunization Confers Robust Antibody Response in Occupational Healthcare Workers and Fosters Workplace Safety. <i>Journal of Occupational and Environmental Medicine</i> , 2021, 63, e314-e317.	0.9	3
48	Human Vaccines & Immunotherapeutics: news. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 618-619.	1.4	0
50	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1160-1168.	0.4	38
52	Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2. <i>Biology</i> , 2021, 10, 208.	1.3	16
54	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021, 27, 717-726.	15.2	838
56	Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 463-476.e6.	5.1	1,054
61	Immunity to SARS-CoV-2: Lessons Learned. <i>Frontiers in Immunology</i> , 2021, 12, 654165.	2.2	33
63	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. <i>Science</i> , 2021, 372, 1413-1418.	6.0	468
64	SARS-CoV-2 - SYNOPTIC CHART OF THE MAIN CHARACTERISTICS OF VIRUS, PATHOGENESIS, IMMUNE RESPONSE, IMMUNOPROPHYLAXIS. <i>Roumanian Archives of Microbiology and Immunology</i> , 2021, 80, 51-80.	0.1	1
66	Back to basics in COVID-19: Antigens and antibodiesâ€”Completing the puzzle. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4523-4533.	1.6	35
68	The great escape? SARS-CoV-2 variants evading neutralizing responses. <i>Cell Host and Microbe</i> , 2021, 29, 322-324.	5.1	78
75	Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. <i>Vaccines</i> , 2021, 9, 243.	2.1	217
81	The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021, 34, 108890.	2.9	200
82	Estimated Half-Life of SARS-CoV-2 Anti-Spike Antibodies More Than Double the Half-Life of Anti-nucleocapsid Antibodies in Healthcare Workers. <i>Clinical Infectious Diseases</i> , 2021, 73, 2366-2368.	2.9	48
87	SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3060.	1.8	32
89	The first 12 months of COVID-19: a timeline of immunological insights. <i>Nature Reviews Immunology</i> , 2021, 21, 245-256.	10.6	325
90	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> , 2021, 593, 130-135.	13.7	1,904

#	ARTICLE	IF	CITATIONS
92	Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. <i>Lancet, The</i> , 2021, 397, 1263-1264.	6.3	49
96	SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. <i>Lancet Microbe, The</i> , 2021, 2, e283-e284.	3.4	344
97	NeutrobodyPlex™ monitoring SARS-CoV-2 neutralizing immune responses using nanobodies. <i>EMBO Reports</i> , 2021, 22, e52325.	2.0	43
98	Pandemic moves and countermoves: vaccines and viral variants. <i>Lancet, The</i> , 2021, 397, 1326-1327.	6.3	29
99	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. <i>Nature Reviews Immunology</i> , 2021, 21, 395-404.	10.6	223
101	Evaluation of a Broad Panel of SARS-CoV-2 Serological Tests for Diagnostic Use. <i>Journal of Clinical Medicine</i> , 2021, 10, 1580.	1.0	7
102	Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective. <i>Biomedicines</i> , 2021, 9, 412.	1.4	22
104	Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization. <i>PLoS Pathogens</i> , 2021, 17, e1009064.	2.1	21
105	SARS-CoV-2 evolution and vaccines: cause for concern?. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 333-335.	5.2	161
106	Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. <i>Science</i> , 2021, 372, .	6.0	2,103
107	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. <i>Science</i> , 2021, 372, 1418-1423.	6.0	286
110	SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	154
112	Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. <i>ACS Nano</i> , 2021, 15, 5793-5818.	7.3	32
113	Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment. <i>European Journal of Haematology</i> , 2021, 107, 24-28.	1.1	16
114	High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1009431.	2.1	34
117	Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. <i>Nature Reviews Immunology</i> , 2021, 21, 330-335.	10.6	98
118	A human coronavirus evolves antigenically to escape antibody immunity. <i>PLoS Pathogens</i> , 2021, 17, e1009453.	2.1	183
122	Structural impact on SARS-CoV-2 spike protein by D614G substitution. <i>Science</i> , 2021, 372, 525-530.	6.0	344

#	ARTICLE	IF	CITATIONS
123	SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. <i>Cell</i> , 2021, 184, 2384-2393.e12.	13.5	848
127	The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?. <i>Expert Review of Vaccines</i> , 2021, 20, 635-638.	2.0	66
128	One year of SARS-CoV-2 evolution. <i>Cell Host and Microbe</i> , 2021, 29, 503-507.	5.1	60
129	SARS-CoV-2 one year on: evidence for ongoing viral adaptation. <i>Journal of General Virology</i> , 2021, 102, .	1.3	137
132	Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1585-1591.	1.4	47
133	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. <i>Biochemistry</i> , 2021, 60, 1459-1484.	1.2	62
134	Killed whole-genome reduced-bacteria surface-expressed coronavirus fusion peptide vaccines protect against disease in a porcine model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	24
136	Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. <i>Science</i> , 2021, 372, 815-821.	6.0	1,125
137	Influenza Virus and SARS-CoV-2 Vaccines. <i>Journal of Immunology</i> , 2021, 206, 2509-2520.	0.4	11
138	BNT162b2 Messenger RNA Vaccination Did Not Prevent an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 Variant 501Y.V2 in an Elderly Nursing Home but Reduced Transmission and Disease Severity. <i>Clinical Infectious Diseases</i> , 2022, 74, 517-520.	2.9	36
139	Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. <i>Science Advances</i> , 2021, 7, .	4.7	113
140	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , 2021, 594, 553-559.	13.7	199
141	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 818-823.	6.0	309
143	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1899-1909.	13.9	541
145	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. <i>Cell Host and Microbe</i> , 2021, 29, 806-818.e6.	5.1	49
147	Antigenic Evolution on a Global Scale Reveals the Potential Natural Selection of Severe Acute Respiratory Syndrome-Coronavirus 2 by Pre-existing Cross-Reactive T-Cell Immunity. <i>Frontiers in Microbiology</i> , 2021, 12, 599562.	1.5	5
148	Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. <i>Expert Review of Vaccines</i> , 2022, 21, 877-884.	2.0	24
149	SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 203.	7.1	65

#	ARTICLE	IF	CITATIONS
153	SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T cell recognition. <i>Cell Reports Medicine</i> , 2021, 2, 100286.	3.3	18
156	Predicting the dynamical behavior of COVID-19 epidemic and the effect of control strategies. <i>Chaos, Solitons and Fractals</i> , 2021, 146, 110823.	2.5	16
157	New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection. <i>Pharmaceuticals</i> , 2021, 14, 503.	1.7	6
158	Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro. <i>Viruses</i> , 2021, 13, 935.	1.5	22
159	Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 35-45.	3.8	634
160	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. <i>Science Immunology</i> , 2021, 6, .	5.6	455
161	Practical guidance for clinical laboratories for SARS-CoV-2 serology testing. <i>Canada Communicable Disease Report</i> , 2021, 47, 171-183.	0.6	12
162	Population (Antibody) Testing for COVID-19 – Technical Challenges, Application and Relevance, an English Perspective. <i>Vaccines</i> , 2021, 9, 550.	2.1	6
163	A preparedness model for the provision of oral health care during unfolding threats: the case of the covid-19 pandemic. <i>BMC Oral Health</i> , 2021, 21, 254.	0.8	4
164	Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	38
165	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 314-338.	6.6	75
166	COVID-19 rise in Bangladesh correlates with increasing detection of B.1.351 variant. <i>BMJ Global Health</i> , 2021, 6, e006012.	2.0	28
167	Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. <i>Cell Reports Medicine</i> , 2021, 2, 100290.	3.3	145
168	Antibodies: what makes us stronger. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3551-3553.	1.4	1
170	Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. <i>Cell Research</i> , 2021, 31, 732-741.	5.7	124
171	SARS-CoV-2 worldwide replication drives rapid rise and selection of mutations across the viral genome: a time-course study – potential challenge for vaccines and therapies. <i>EMBO Molecular Medicine</i> , 2021, 13, e14062.	3.3	28
172	Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e1397-e1401.	2.9	44
175	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein. <i>Glycobiology</i> , 2021, 31, 1080-1092.	1.3	31

#	ARTICLE	IF	CITATIONS
178	Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins. <i>Scientific Reports</i> , 2021, 11, 10475.	1.6	6
179	Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. <i>Frontiers in Immunology</i> , 2021, 12, 688436.	2.2	26
181	Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation. <i>Npj Vaccines</i> , 2021, 6, 71.	2.9	23
185	Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 72-82.	2.7	11
186	Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2. <i>Vaccines</i> , 2021, 9, 498.	2.1	10
188	Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5464.	1.8	9
190	On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021, 557, 70-85.	1.1	38
191	<scp>COVID</scp>â€19: vaccination problems. <i>Environmental Microbiology</i> , 2021, 23, 2878-2890.	1.8	46
192	Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. <i>Nature Communications</i> , 2021, 12, 3109.	5.8	118
193	COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. <i>Human Genomics</i> , 2021, 15, 27.	1.4	39
195	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 1205-1211.	15.2	3,133
196	Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals. <i>Viruses</i> , 2021, 13, 1135.	1.5	17
200	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. <i>Molecules and Cells</i> , 2021, 44, 392-400.	1.0	22
201	A newly identified linear epitope on non-RBD region of SARS-CoV-2 spike protein improves the serological detection rate of COVID-19 patients. <i>BMC Microbiology</i> , 2021, 21, 194.	1.3	8
202	Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring K417T/E484K/N501Y mutations in Kofu, Japan. <i>Journal of Infection</i> , 2021, 82, 276-316.	1.7	57
203	COVID-19 vaccination in pediatric solid organ transplant recipientsâ€”Current state and future directions. <i>Pediatric Transplantation</i> , 2021, 25, e14031.	0.5	4
204	Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021. <i>MSystems</i> , 2021, 6, e0035321.	1.7	46
205	Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. <i>Nature Communications</i> , 2021, 12, 3815.	5.8	44

#	ARTICLE	IF	CITATIONS
207	Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. <i>EBioMedicine</i> , 2021, 68, 103403.	2.7	102
208	Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern. <i>American Journal of Pathology</i> , 2021, 191, 983-992.	1.9	42
209	Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil. <i>Viruses</i> , 2021, 13, 1237.	1.5	23
210	The Immunopathobiology of SARS-CoV-2 Infection. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	9
211	The significance and impact of SARS-CoV-2 variants of concern in pediatric solid organ transplantation: More unknowns than knowns. <i>Pediatric Transplantation</i> , 2021, 25, e14071.	0.5	1
213	COVID-19 vaccines: Frequently asked questions and updated answers. <i>Infectious Diseases Now</i> , 2021, 51, 319-333.	0.7	10
214	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. <i>Science Immunology</i> , 2021, 6, eabj1031.	5.6	223
215	Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	198
216	Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2 in humans and mice. <i>European Journal of Immunology</i> , 2021, 51, 2296-2305.	1.6	7
217	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
218	Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 701752.	2.2	17
219	SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i> , 2021, 19, 409-424.	13.6	2,650
220	An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. <i>Scientific Reports</i> , 2021, 11, 12740.	1.6	54
222	Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients. , 2021, 9, e002932.		7
223	Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design. <i>Frontiers in Immunology</i> , 2021, 12, 710263.	2.2	32
224	A conceptual approach to the rationale for SARS-CoV-2 vaccine allocation prioritisation. <i>Pathogens and Global Health</i> , 2021, 115, 1-4.	1.0	1
225	Smartphone screen testing, a novel pre-diagnostic method to identify SARS-CoV-2 infectious individuals. <i>ELife</i> , 2021, 10, .	2.8	9
226	Using mixed-effects modeling to estimate decay kinetics of response to SARS-CoV-2 infection. <i>Antibody Therapeutics</i> , 2021, 4, 144-148.	1.2	6



#	ARTICLE	IF	CITATIONS
228	The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 704773.	2.2	54
229	Phenotypes and Functions of SARS-CoV-2-Reactive T Cells. <i>Molecules and Cells</i> , 2021, 44, 401-407.	1.0	16
230	Novel Highly Divergent SARS-CoV-2 Lineage With the Spike Substitutions L249S and E484K. <i>Frontiers in Medicine</i> , 2021, 8, 697605.	1.2	6
231	Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. <i>Science</i> , 2021, 373, .	6.0	318
232	Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan. <i>PLoS Pathogens</i> , 2021, 17, e1009619.	2.1	40
233	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108.	13.7	222
236	Less Frequent Sequence Mismatches in Variants of Concern (VOCs) of SARS-CoV-2 in the Real-Time RT-PCR Assays Developed by the National Institute of Infectious Diseases, Japan. <i>Japanese Journal of Infectious Diseases</i> , 2022, 75, 96-101.	0.5	4
237	Inhibitory effect on SARS-CoV-2 infection of neferine by blocking Ca <sup>2+</sup> -dependent membrane fusion. <i>Journal of Medical Virology</i> , 2021, 93, 5825-5832.	2.5	20
238	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 233.	7.1	203
239	Lack of Informations about COVID-19 Vaccine: From Implications to Intervention for Supporting Public Health Communications in COVID-19 Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6141.	1.2	15
240	Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2021, 12, 691715.	2.2	76
242	SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions. <i>Scientific Reports</i> , 2021, 11, 11998.	1.6	17
245	Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern. <i>Comptes Rendus - Biologies</i> , 2021, 344, 77-110.	0.1	4
250	COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials. <i>Expert Review of Vaccines</i> , 2021, 20, 857-880.	2.0	32
251	Metal Complexes as Antiviral Agents for SARS-CoV-2. <i>ChemBioChem</i> , 2021, 22, 2600-2607.	1.3	45
252	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021, 184, 3086-3108.	13.5	309
253	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021, 595, 426-431.	13.7	610
256	COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. <i>Molecular Biotechnology</i> , 2021, 63, 885-897.	1.3	8

#	ARTICLE	IF	CITATIONS
258	VirusViz: comparative analysis and effective visualization of viral nucleotide and amino acid variants. <i>Nucleic Acids Research</i> , 2021, 49, e90-e90.	6.5	18
259	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 3991.	5.8	241
260	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. <i>Cell</i> , 2021, 184, 3205-3221.e24.	13.5	73
261	Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 226.	7.1	103
262	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 278-282.	13.7	154
263	Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. <i>Clinical Infectious Diseases</i> , 2021, 73, 2000-2008.	2.9	30
264	Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. <i>Cell</i> , 2021, 184, 3426-3437.e8.	13.5	424
265	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2370.	3.8	307
266	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. <i>New England Journal of Medicine</i> , 2021, 384, 2212-2218.	13.9	647
267	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	6.0	174
269	Human immunoglobulin from transchromosomal bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	20
270	Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells. <i>Cells</i> , 2021, 10, 1761.	1.8	34
272	Molecular Diagnosis of SARS-CoV-2: Assessing and Interpreting Nucleic Acid and Antigen Tests. <i>Pathogens and Immunity</i> , 2021, 6, 135-156.	1.4	10
274	How to interpret and use COVID-19 serology and immunology tests. <i>Clinical Microbiology and Infection</i> , 2021, 27, 981-986.	2.8	94
275	The variants question: What is the problem?. <i>Journal of Medical Virology</i> , 2021, 93, 6479-6485.	2.5	26
276	Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsortâ€19 study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 271-281.	2.7	30
278	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021, 373, 648-654.	6.0	385
279	Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern. <i>JCI Insight</i> , 2021, 6, .	2.3	32

#	ARTICLE	IF	CITATIONS
280	Individual HLA-A, -B, -C, and -DRB1 Genotypes Are No Major Factors Which Determine COVID-19 Severity. <i>Frontiers in Immunology</i> , 2021, 12, 698193.	2.2	15
281	An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. <i>Cell Reports</i> , 2021, 36, 109452.	2.9	90
282	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009688.	2.1	16
284	Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection. <i>Vaccines</i> , 2021, 9, 742.	2.1	39
285	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T <sub>H</sub> cell responses. <i>Cell Host and Microbe</i> , 2021, 29, 1137-1150.e6.	5.1	173
288	Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. <i>Reviews in Medical Virology</i> , 2022, 32, e2277.	3.9	57
289	COVID-19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances. <i>Obesity Reviews</i> , 2021, 22, e13313.	3.1	32
292	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 36, 109415.	2.9	206
293	Antibody and B cell responses to SARS-CoV-2 infection and vaccination. <i>Cell Host and Microbe</i> , 2021, 29, 1063-1075.	5.1	99
294	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021, 12, 4196.	5.8	332
295	Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T <sub>H</sub> cell reactivity in infected or vaccinated individuals. <i>Cell Reports Medicine</i> , 2021, 2, 100355.	3.3	490
300	Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. <i>Nature</i> , 2021, 597, 268-273.	13.7	279
302	Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 1498.	1.5	33
304	Usefulness of IVD Kits for the Assessment of SARS-CoV-2 Antibodies to Evaluate the Humoral Response to Vaccination. <i>Vaccines</i> , 2021, 9, 840.	2.1	33
308	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. <i>Cell Reports</i> , 2021, 36, 109450.	2.9	38
310	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021, 597, 103-108.	13.7	220
311	SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. <i>Cell</i> , 2021, 184, 3936-3948.e10.	13.5	241
312	An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status. <i>Clinical Infectious Diseases</i> , 2022, 74, 1208-1219.	2.9	64

#	ARTICLE	IF	CITATIONS
313	Rise and Fall of SARS-CoV-2 Lineage A.27 in Germany. <i>Viruses</i> , 2021, 13, 1491.	1.5	9
314	The COVID-19 world "Are we there yet?". <i>Journal of Diabetes Investigation</i> , 2021, 12, 1125-1127.	1.1	4
315	Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4210.	5.8	82
316	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 288.	7.1	38
318	Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. <i>Vaccines</i> , 2021, 9, 836.	2.1	15
319	Coding-Complete Genome Sequences of 11 SARS-CoV-2 B.1.1.7 and B.1.351 Variants from Metro Manila, Philippines. <i>Microbiology Resource Announcements</i> , 2021, 10, e0049821.	0.3	5
320	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. <i>Cell Host and Microbe</i> , 2021, 29, 1151-1161.e5.	5.1	36
321	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. <i>Immunity</i> , 2021, 54, 1611-1621.e5.	6.6	190
322	Catching SARS-CoV-2 by Sequence Hybridization: a Comparative Analysis. <i>MSystems</i> , 2021, 6, e0039221.	1.7	11
325	The COVID-19 vaccine development: A pandemic paradigm. <i>Virus Research</i> , 2021, 301, 198454.	1.1	24
326	Rapid evolution of the COVID-19 pandemic calls for a unified public health response. <i>BioScience Trends</i> , 2021, 15, 196-200.	1.1	5
328	Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. <i>Cell Reports</i> , 2021, 36, 109604.	2.9	67
330	Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. , 2022, 230, 107967.		40
331	Immunity to SARS-CoV-2 induced by infection or vaccination. <i>Journal of Internal Medicine</i> , 2022, 291, 32-50.	2.7	97
332	B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies. <i>MBio</i> , 2021, 12, e0138621.	1.8	52
333	Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. <i>Cell</i> , 2021, 184, 4401-4413.e10.	13.5	65
334	Fragment molecular orbital based interaction analyses on complexes between SARS-CoV-2 RBD variants and ACE2. <i>Japanese Journal of Applied Physics</i> , 2021, 60, 090901.	0.8	8
336	Molecular Level Dissection of Critical Spike Mutations in SARS-CoV-2 Variants of Concern (VOCs): A Simplified Review. <i>ChemistrySelect</i> , 2021, 6, 7981-7998.	0.7	18

#	ARTICLE	IF	CITATIONS
337	Mask-off policy in the shadow of emerging variants of SARS-CoV-2. <i>European Journal of Internal Medicine</i> , 2021, 90, 109-110.	1.0	1
338	Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes. <i>Nature Communications</i> , 2021, 12, 4676.	5.8	74
340	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. <i>Nature Communications</i> , 2021, 12, 4886.	5.8	65
342	Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 788-796.	2.8	40
343	Engineering of single-domain antibodies for next-generation snakebite antivenoms. <i>International Journal of Biological Macromolecules</i> , 2021, 185, 240-250.	3.6	9
344	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. <i>JCI Insight</i> , 2021, 6, .	2.3	33
345	Pressing Questions and Challenges in the HIV-1 and SARS-CoV-2 Syndemic. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 589-600.	0.5	5
346	Case Report: Severe COVID-19 in a Kidney Transplant Recipient Without Humoral Response to SARS-CoV-2 mRNA Vaccine Series. <i>Transplantation Direct</i> , 2021, 7, e743.	0.8	3
347	Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies. <i>PLoS ONE</i> , 2021, 16, e0253574.	1.1	10
348	SARS-CoV-2 vaccines "the biggest medical research project of the 21st century. <i>Current Opinion in Virology</i> , 2021, 49, 52-57.	2.6	12
349	The impact of high-resolution structural data on stemming the COVID-19 pandemic. <i>Current Opinion in Virology</i> , 2021, 49, 127-138.	2.6	2
350	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
354	Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. <i>ELife</i> , 2021, 10, .	2.8	267
355	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021, 54, 1853-1868.e7.	6.6	230
356	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. <i>Nature Reviews Immunology</i> , 2021, 21, 626-636.	10.6	777
358	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5061.	5.8	150
359	Evolutionary trajectory of SARS-CoV-2 and emerging variants. <i>Virology Journal</i> , 2021, 18, 166.	1.4	105
361	Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer. <i>American Journal of Clinical Pathology</i> , 2022, 157, 109-118.	0.4	5

#	ARTICLE	IF	CITATIONS
362	BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 759-762.	0.3	112
364	Physiologic Response to the Pfizer-BioNTech COVID-19 Vaccine Measured Using Wearable Devices: Prospective Observational Study. <i>JMIR Formative Research</i> , 2021, 5, e28568.	0.7	13
365	Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization. <i>Cell Discovery</i> , 2021, 7, 64.	3.1	22
366	The rapid adaptation of SARS-CoV-2 "rise of the variants: transmission and resistance. <i>Journal of Microbiology</i> , 2021, 59, 807-818.	1.3	18
367	Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Cases Corroborated by Sequencing. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	8
368	The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. <i>Exploration of Immunology</i> , 2021, , 199-225.	1.7	5
370	mRNA vaccines for infectious diseases: principles, delivery and clinical translation. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 817-838.	21.5	577
371	Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. <i>Military Medical Research</i> , 2021, 8, 47.	1.9	88
372	Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals. <i>Frontiers in Immunology</i> , 2021, 12, 722766.	2.2	20
374	SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	251
376	Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers. <i>Microorganisms</i> , 2021, 9, 1725.	1.6	48
377	Potential SARS-CoV-2 vaccines: Concept, progress, and challenges. <i>International Immunopharmacology</i> , 2021, 97, 107622.	1.7	14
378	Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies. <i>PLoS ONE</i> , 2021, 16, e0255622.	1.1	21
380	Development and Evaluation of a Set of Spike and Receptor Binding Domain-Based Enzyme-Linked Immunosorbent Assays for SARS-CoV-2 Serological Testing. <i>Diagnostics</i> , 2021, 11, 1506.	1.3	10
381	Remote HRI: a Methodology for Maintaining COVID-19 Physical Distancing and Human Interaction Requirements in HRI Studies. <i>Information Systems Frontiers</i> , 2024, 26, 91-106.	4.1	14
382	Disappearance of Seasonal Respiratory Viruses in Children Under Two Years Old During COVID-19 Pandemic: A Monocentric Retrospective Study in Milan, Italy. <i>Frontiers in Pediatrics</i> , 2021, 9, 721005.	0.9	38
383	Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. <i>MSphere</i> , 2021, 6, e0048021.	1.3	70
385	NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments. <i>Frontiers in Pharmacology</i> , 2021, 12, 708302.	1.6	37

#	ARTICLE	IF	CITATIONS
386	Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques. <i>MBio</i> , 2021, 12, e0150321.	1.8	28
387	Novel SARS-CoV-2 variants: the pandemics within the pandemic. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1109-1117.	2.8	290
388	Partial protection of Sinopharm vaccine against SARS COV2 during recent outbreak in Bahrain. <i>Microbial Pathogenesis</i> , 2021, 158, 105086.	1.3	15
389	Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains. <i>Cytotherapy</i> , 2022, 24, 10-15.	0.3	6
390	Genomic surveillance to combat COVID-19: challenges and opportunities. <i>Lancet Microbe</i> , The, 2021, 2, e481-e484.	3.4	122
391	A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. <i>European Journal of Immunology</i> , 2022, 52, 770-783.	1.6	24
392	Anti-SARS-CoV-2 Activity of Extracellular Vesicle Inhibitors: Screening, Validation, and Combination with Remdesivir. <i>Biomedicines</i> , 2021, 9, 1230.	1.4	8
393	Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants. <i>PLoS Computational Biology</i> , 2021, 17, e1009380.	1.5	13
395	S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 343.	7.1	24
396	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. <i>Immunity</i> , 2021, 54, 2159-2166.e6.	6.6	52
398	Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. <i>Nature</i> , 2021, 599, 465-470.	13.7	129
399	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100405.	3.3	110
400	SARS-CoV-2 Spike Protein Mutations and Escape from Antibodies: A Computational Model of Epitope Loss in Variants of Concern. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4687-4700.	2.5	26
401	An ultrapotent pan- $\beta$ -coronavirus lineage B ( $\beta$ -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
403	Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction. <i>Journal of Biological Chemistry</i> , 2021, 297, 101202.	1.6	28
405	Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience. <i>Journal of Medical Virology</i> , 2022, 94, 287-290.	2.5	34
407	The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 737083.	2.2	18
408	BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 999-1009.	5.2	279

#	ARTICLE	IF	CITATIONS
409	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021, 6, 1233-1244.	5.9	237
410	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. <i>Science Advances</i> , 2021, 7, eabj5365.	4.7	83
411	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. <i>Science</i> , 2021, 374, 472-478.	6.0	228
412	Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. <i>Vaccines</i> , 2021, 9, 1017.	2.1	10
413	A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease. <i>Cell Reports</i> , 2021, 36, 109754.	2.9	30
414	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	44
416	Emergence of SARS-CoV-2 Variant B.1.575.2, Containing the E484K Mutation in the Spike Protein, in Pamplona, Spain, May to June 2021. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0173621.	1.8	2
417	Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin) Tj ETQq1 1 0.784314 rgBT /Overlock 19	2.0	19
418	Interactions of the Receptor Binding Domain of SARS-CoV-2 Variants with hACE2: Insights from Molecular Docking Analysis and Molecular Dynamic Simulation. <i>Biology</i> , 2021, 10, 880.	1.3	38
419	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. <i>Science Immunology</i> , 2021, 6, eabj2901.	5.6	67
420	The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. <i>Cell</i> , 2021, 184, 5189-5200.e7.	13.5	186
421	Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 301.e1-301.e8.	2.8	28
422	Shooting at a Moving Targetâ€”Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 1052.	2.1	22
423	Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. <i>Bioscience Reports</i> , 2021, 41, .	1.1	28
424	SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. <i>Vaccine</i> , 2021, 39, 5769-5779.	1.7	23
425	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
426	TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351). <i>Microbiology Spectrum</i> , 2021, 9, e0047221.	1.2	21
428	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87



#	ARTICLE	IF	CITATIONS
430	A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels. <i>Scientific Reports</i> , 2021, 11, 18428.	1.6	10
432	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	16
433	The Immune Response to SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2021, 13, 1911.	1.5	18
434	Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants. <i>Journal of Biological Chemistry</i> , 2021, 297, 101208.	1.6	37
435	Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. <i>Cell</i> , 2021, 184, 4969-4980.e15.	13.5	94
436	WHotLAMP: A simple, inexpensive, and sensitive molecular test for the detection of SARS-CoV-2 in saliva. <i>PLoS ONE</i> , 2021, 16, e0257464.	1.1	2
437	Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation. <i>Journal of Virology</i> , 2021, 95, e0096621.	1.5	17
438	Coronavirus Disease 2019 Vaccine Impact on Rates of Severe Acute Respiratory Syndrome Coronavirus 2 Cases and Postvaccination Strain Sequences Among Health Care Workers at an Urban Academic Medical Center: A Prospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab465.	0.4	38
439	Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals. <i>JCI Insight</i> , 2021, 6, .	2.3	18
440	The Metabolic Response of Various Cell Lines to Microtubule-Driven Uptake of Lipid- and Polymer-Coated Layer-by-Layer Microcarriers. <i>Pharmaceutics</i> , 2021, 13, 1441.	2.0	1
441	Prevention of host-to-host transmission by SARS-CoV-2 vaccines. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e52-e58.	4.6	59
443	Allosteric Control of Structural Mimicry and Mutational Escape in the SARS-CoV-2 Spike Protein Complexes with the ACE2 Decoys and Miniprotein Inhibitors: A Network-Based Approach for Mutational Profiling of Binding and Signaling. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5172-5191.	2.5	26
444	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009701.	2.1	12
445	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28
446	A hitchhiker's guide through the COVID-19 galaxy. <i>Clinical Immunology</i> , 2021, 232, 108849.	1.4	3
447	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. <i>EBioMedicine</i> , 2021, 72, 103581.	2.7	184
449	Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. <i>Cell Reports</i> , 2021, 37, 109822.	2.9	35
450	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	13.5	131

#	ARTICLE	IF	CITATIONS
453	A look into the future of the COVID-19 pandemic in Europe: an expert consultation. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100185.	3.0	72
454	Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	61
455	Precision Response to the Rise of the SARS-CoV-2 B.1.1.7 Variant of Concern by Combining Novel PCR Assays and Genome Sequencing for Rapid Variant Detection and Surveillance. <i>Microbiology Spectrum</i> , 2021, 9, e0031521.	1.2	35
456	Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. <i>Microbiology Spectrum</i> , 2021, 9, e0034121.	1.2	114
457	Broad betacoronavirus neutralization by a stem helix-specific human antibody. <i>Science</i> , 2021, 373, 1109-1116.	6.0	262
458	Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development. <i>International Reviews of Immunology</i> , 2022, 41, 393-413.	1.5	13
459	Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies. <i>Journal of Medical Virology</i> , 2022, 94, 399-403.	2.5	23
460	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , 2021, 600, 512-516.	13.7	174
461	Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody. <i>Frontiers in Immunology</i> , 2021, 12, 751584.	2.2	11
462	Near real-time determination of B.1.1.7 in proportion to total SARS-CoV-2 viral load in wastewater using an allele-specific primer extension PCR strategy. <i>Water Research</i> , 2021, 205, 117681.	5.3	48
464	A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. <i>Antiviral Research</i> , 2021, 194, 105147.	1.9	11
465	Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected. <i>Journal of Infection</i> , 2021, 83, 467-472.	1.7	28
466	COVID-19, the first pandemic in the post-genomic era. <i>Current Opinion in Virology</i> , 2021, 50, 40-48.	2.6	40
467	Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries. <i>International Immunopharmacology</i> , 2021, 99, 108050.	1.7	14
468	Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry. <i>Pharmacological Research</i> , 2021, 172, 105820.	3.1	50
469	Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. <i>Lancet Microbe</i> , The, 2021, 2, e527-e535.	3.4	92
470	The existence, spread, and strategies for environmental monitoring and control of SARS-CoV-2 in environmental media. <i>Science of the Total Environment</i> , 2021, 795, 148949.	3.9	4
471	The challenge of screening SARS-CoV-2 variants of concern with RT-qPCR: One variant can hide another. <i>Journal of Virological Methods</i> , 2021, 297, 114248.	1.0	8

#	ARTICLE	IF	CITATIONS
472	Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. <i>Infection, Genetics and Evolution</i> , 2021, 95, 105038.	1.0	110
473	COVID-19 variants in India: Potential role in second wave and impact on vaccination. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2021, 50, 784-787.	0.8	24
474	Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test. <i>One Health</i> , 2021, 13, 100313.	1.5	28
475	E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 109, 108035.	1.3	52
476	Comparative Analysis of SARS-CoV-2-Specific B Cell and Humoral Responses Elicited by Sputnik V in Naïve and COVID-19-Recovered Vaccine Recipients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
477	A New SARS-CoV-2 Variant Poorly Detected by RT-PCR on Nasopharyngeal Samples, with High Lethality. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
478	Effectiveness of BNT162b2 mRNA COVID-19 Vaccine Against SARS-CoV-2 Variant Beta (B.1.351) Among Persons Identified Through Contact Tracing in Israel. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
479	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqab010.	1.2	18
481	Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	8
482	The emerging SARS-CoV-2 variants of concern. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110243.	1.1	82
485	COVID-19 mRNA Based Vaccine Immune-Response Assessment for Public Health Decision. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
486	SARS-CoV-2 Variants of Concern. <i>Yonsei Medical Journal</i> , 2021, 62, 961.	0.9	183
487	Divergence of Delta and Beta Variants and SARS-CoV-2 Evolved in Advanced HIV Disease into Two Serological Phenotypes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
488	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
489	Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination. <i>BMC Clinical Pathology</i> , 2021, 14, 2632010X2110492.	0.7	9
490	Global Prevalence of Adaptive and Prolonged Infectionsâ€™ Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. <i>Viruses</i> , 2021, 13, 1974.	1.5	9
491	Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 346.	7.1	60
492	Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 757197.	2.2	20

#	ARTICLE	IF	CITATIONS
493	INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2021, 6, 121.	2.9	36
494	Pfizer/BioNTech-associated perniois in two young adults with rechallenge evidence. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
495	Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. <i>Science Immunology</i> , 2021, 6, eabl5842.	5.6	33
496	Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission. <i>Science Immunology</i> , 2021, 6, eabm3131.	5.6	37
497	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. <i>Npj Vaccines</i> , 2021, 6, 125.	2.9	17
498	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
500	Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2. <i>Life</i> , 2021, 11, 1125.	1.1	6
501	Genomic surveillance of SARS-CoV-2 tracks early interstate transmission of P.1 lineage and diversification within P.2 clade in Brazil. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009835.	1.3	23
502	Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. <i>Nature</i> , 2021, 600, 523-529.	13.7	194
504	Providing children with COVID-19 vaccinations is challenging due to lack of data and wide-ranging parental acceptance. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 111, 35.	0.7	16
505	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021, 600, 517-522.	13.7	239
506	Actions and attitudes on the immunized patients against SARS-CoV-2. <i>Revista Espanola De Quimioterapia</i> , 2021, , .	0.5	3
507	The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization. <i>Molecular Biology Reports</i> , 2022, 49, 647-656.	1.0	11
508	In vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential. <i>Cell Reports</i> , 2021, 37, 109838.	2.9	8
509	A new SARS-CoV-2 variant with high lethality poorly detected by RT-PCR on nasopharyngeal samples: an observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 298.e9-298.e15.	2.8	13
510	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	16.1	1,532
511	Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro. <i>FASEB Journal</i> , 2021, 35, e21970.	0.2	22
513	The global epidemic of SARS-CoV-2 variants and their mutational immune escape. <i>Journal of Medical Virology</i> , 2022, 94, 847-857.	2.5	80

#	ARTICLE	IF	CITATIONS
515	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1450-1466.	5.2	110
516	Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening. <i>Scientific Reports</i> , 2021, 11, 20738.	1.6	11
517	Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants. <i>MBio</i> , 2021, 12, e0181321.	1.8	28
518	Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination. <i>American Journal of Hematology</i> , 2022, 97, E3.	2.0	12
519	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
520	Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy. <i>Advanced Materials</i> , 2021, 33, e2103471.	11.1	60
521	Vaccines against COVID-19: Priority to mRNA-Based Formulations. <i>Cells</i> , 2021, 10, 2716.	1.8	17
523	Stabilized coronavirus spike stem elicits a broadly protective antibody. <i>Cell Reports</i> , 2021, 37, 109929.	2.9	64
524	2021 Interim Guidance to Health Care Providers for Basic and Advanced Cardiac Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008396.	0.9	21
527	Clinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS) Tj ETQq1 1 0.784314 rgBT /Overlooked Diseases, 2022, 75, e774-e782.	2.9	5
529	Vaccine breakthrough infections in veterans hospitalized with coronavirus infectious disease-2019: A case series. <i>American Journal of Infection Control</i> , 2022, 50, 273-276.	1.1	6
530	Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. <i>Science Advances</i> , 2021, 7, eabj3107.	4.7	23
534	The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 744887.	2.2	68
535	Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. <i>Cell Reports</i> , 2021, 37, 109881.	2.9	14
536	Analysis of IgG, IgA and IgM antibodies against SARS-CoV-2 spike protein S1 in convalescent and vaccinated patients with the Pfizer-BioNTech and CanSinoBio vaccines. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	1.3	9
537	Vaccine development and technology for SARS-CoV-2: Current insight. <i>Journal of Medical Virology</i> , 2022, 94, 878-896.	2.5	8
538	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	5.7	123
539	Epithelial-mesenchymal transition and its transcription factors. <i>Bioscience Reports</i> , 2022, 42, .	1.1	79

#	ARTICLE	IF	CITATIONS
540	SARS-CoV-2 beta variant substitutions alter spike glycoprotein receptor binding domain structure and stability. <i>Journal of Biological Chemistry</i> , 2021, 297, 101371.	1.6	6
541	High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 2177.	1.5	21
542	RT-qPCR assays for SARS-CoV-2 variants of concern in wastewater reveals compromised vaccination-induced immunity. <i>Water Research</i> , 2021, 207, 117808.	5.3	39
543	Evaluation of the QuantIFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5148-5149.	1.4	15
544	Viral vector-based vaccines against SARS-CoV-2. <i>Exploration of Immunology</i> , 2021, , 295-308.	1.7	4
545	Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. <i>Immunity</i> , 2021, 54, 2908-2921.e6.	6.6	35
546	Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. <i>IScience</i> , 2021, 24, 103393.	1.9	17
547	Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine Escape. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
548	Immuno-informatics analysis predicts B and T cell consensus epitopes for designing peptide vaccine against SARS-CoV-2 with 99.82% global population coverage. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	5
549	Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections. <i>Frontiers in Immunology</i> , 2021, 12, 742167.	2.2	32
550	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. <i>Scientific Reports</i> , 2021, 11, 21601.	1.6	20
551	Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. <i>Nature Communications</i> , 2021, 12, 6405.	5.8	128
552	Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model. <i>EBioMedicine</i> , 2021, 73, 103675.	2.7	26
553	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, eabj7125.	5.8	93
555	SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response. <i>Emerging Microbes and Infections</i> , 2021, 10, 2235-2243.	3.0	31
556	BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. <i>Science Immunology</i> , 2021, 6, eabl5344.	5.6	166
557	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
558	Circulation and Evolution of SARS-CoV-2 in India: Let the Data Speak. <i>Viruses</i> , 2021, 13, 2238.	1.5	8

#	ARTICLE	IF	CITATIONS
560	Rationally Designed Immunogens Enable Immune Focusing Following SARS-CoV-2 Spike Imprinting. SSRN Electronic Journal, 0, , .	0.4	0
561	D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity. Applied Microbiology and Biotechnology, 2021, 105, 9035-9045.	1.7	34
562	Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern. Cell Reports, 2021, 37, 110114.	2.9	44
563	When Do We Need Massive Computations to Perform Detailed COVID-19 Simulations?. Advanced Theory and Simulations, 2022, 5, 2100343.	1.3	8
564	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. Archives of Virology, 2022, 167, 293-305.	0.9	28
565	Multifunctional Dendronized Polypeptides for Controlled Adjuvanticity. Biomacromolecules, 2021, , .	2.6	5
566	Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale. Journal of General Virology, 2021, 102, .	1.3	0
567	Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination. Rheumatology, 2022, 61, 3439-3447.	0.9	12
568	Immune response against SARS-CoV-2 variants: the role of neutralization assays. Npj Vaccines, 2021, 6, 142.	2.9	26
569	A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge. Cell Reports, 2021, 37, 110112.	2.9	22
570	Nature of Acquired Immune Responses, Epitope Specificity and Resultant Protection from SARS-CoV-2. Journal of Personalized Medicine, 2021, 11, 1253.	1.1	3
572	COVID-19 epidemic control using short-term lockdowns for collective gain. Annual Reviews in Control, 2021, 52, 573-586.	4.4	7
573	SARS-CoV-2 Targets and COVID-19 Vaccines. Covid, 2021, 1, 608-621.	0.7	4
574	Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance. Current Opinion in Pharmacology, 2022, 62, 64-73.	1.7	29
575	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Seminars in Immunology, 2021, 55, 101533.	2.7	72
576	Nanoparticulate CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice. International Journal of Biological Macromolecules, 2021, 193, 1885-1897.	3.6	12
577	Antibody cocktail effective against variants of SARS-CoV-2. Journal of Biomedical Science, 2021, 28, 80.	2.6	17
578	Covid-19 vaccines and variants of concern: A review. Reviews in Medical Virology, 2022, 32, e2313.	3.9	201

#	ARTICLE	IF	CITATIONS
579	A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. <i>Nature</i> , 2022, 601, 617-622.	13.7	153
580	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. <i>Microbiology Spectrum</i> , 2021, 9, e0109621.	1.2	39
581	Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 273-278.	0.8	19
582	Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. <i>MBio</i> , 2021, 12, e0297521.	1.8	24
583	Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies. <i>Cell Discovery</i> , 2021, 7, 112.	3.1	14
585	Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations. <i>Frontiers in Immunology</i> , 2021, 12, 730099.	2.2	15
587	High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. <i>Microbiology Spectrum</i> , 2021, 9, e0096521.	1.2	17
588	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 793953.	2.2	25
589	Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2. <i>MBio</i> , 2021, 12, e0231521.	1.8	6
590	Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study. <i>EClinicalMedicine</i> , 2021, 42, 101190.	3.2	22
591	E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody. <i>International Immunopharmacology</i> , 2022, 102, 108424.	1.7	31
592	The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. <i>Biochemical Society Transactions</i> , 2021, 49, 2879-2890.	1.6	16
593	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
594	Spherical Neutralizing Aptamer Inhibits SARS-CoV-2 Infection and Suppresses Mutational Escape. <i>Journal of the American Chemical Society</i> , 2021, 143, 21541-21548.	6.6	56
595	Introduction and rapid dissemination of SARS-CoV-2 Gamma Variant of Concern in Venezuela. <i>Infection, Genetics and Evolution</i> , 2021, 96, 105147.	1.0	13
596	The mystery of COVID-19 reinfections: A global systematic review and meta-analysis. <i>Annals of Medicine and Surgery</i> , 2021, 72, 103130.	0.5	31
597	Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. <i>PLoS Pathogens</i> , 2021, 17, e1010022.	2.1	139
598	Rapid test to assess the escape of SARS-CoV-2 variants of concern. <i>Science Advances</i> , 2021, 7, eabl7682.	4.7	21



#	ARTICLE	IF	CITATIONS
599	The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. <i>Journal of Functional Foods</i> , 2021, 87, 104850.	1.6	23
600	Persistent B-Cell Memory After SARS-CoV-2 Vaccination is Functional During Breakthrough Infections. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
601	Waning of Serum Antibodies, But Increase of Protective B-Cell Memory Nine Months After BNT162b2 Vaccination. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
602	Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. , 2021, 9, 251513552110597.	1.4	15
603	Rapid and Parallel Adaptive Mutations in Spike S1 Drive Clade Success in SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
604	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. <i>Nanoscale</i> , 2022, 14, 1054-1074.	2.8	22
605	The dynamic change of SARS-CoV-2 variants in Sierra Leone. <i>Infection, Genetics and Evolution</i> , 2022, 98, 105208.	1.0	5
606	Nanoscale self-assembly: concepts, applications and challenges. <i>Nanotechnology</i> , 2022, 33, 132001.	1.3	32
607	Outcome of SARS-CoV-2 variant breakthrough infection in fully immunized solid organ transplant recipients. <i>Journal of Infection and Public Health</i> , 2022, 15, 51-55.	1.9	7
608	Basic Research Reveals the Unique Virologic Features of SARS-CoV-2. <i>Trends in the Sciences</i> , 2021, 26, 9_79-9_86.	0.0	0
609	Primer of COVID-19 Vaccines for the Perioperative Physician. <i>Journal of Neurosurgical Anesthesiology</i> , 2022, 34, 101-106.	0.6	0
610	Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. <i>Nature Medicine</i> , 2022, 28, 496-503.	15.2	215
611	Molecular Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 Isolates From Central Inner Sardinia. <i>Frontiers in Microbiology</i> , 2021, 12, 827799.	1.5	3
612	Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. <i>Cell Host and Microbe</i> , 2022, 30, 400-408.e4.	5.1	75
613	Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 816220.	2.2	22
614	An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. <i>RSC Medicinal Chemistry</i> , 2022, 13, 647-675.	1.7	3
615	Innovative vaccine approachesâ€”a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2022, 1511, 59-86.	1.8	5
617	Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. <i>Nature</i> , 2022, 603, 919-925.	13.7	146

#	ARTICLE	IF	CITATIONS
618	The "LLQY" motif on SARS-CoV-2 spike protein affects S incorporation into virus particles. <i>Journal of Virology</i> , 2022, , jvi0189721.	1.5	1
619	Quantum optical immunoassay: upconversion nanoparticle-based neutralizing assay for COVID-19. <i>Scientific Reports</i> , 2022, 12, 1263.	1.6	8
621	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1242-1252.e12.	1.5	23
622	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
623	Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2. <i>Journal of Biological Chemistry</i> , 2022, 298, 101658.	1.6	12
624	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
625	From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. <i>Nano-Micro Letters</i> , 2022, 14, 41.	14.4	26
626	Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. <i>EBioMedicine</i> , 2022, 75, 103805.	2.7	60
627	Unique Evolution of SARS-CoV-2 in the Second Large Cruise Ship Cluster in Japan. <i>Microorganisms</i> , 2022, 10, 99.	1.6	2
628	Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein. <i>Structure</i> , 2022, 30, 590-607.e4.	1.6	24
630	SARS-CoV-2 transmission dynamics and immune responses in a household of vaccinated persons. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	1
632	Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination. <i>Clinical Infection in Practice</i> , 2022, 13, 100130.	0.2	11
633	Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges. <i>Nature Communications</i> , 2022, 13, 140.	5.8	22
634	A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination. <i>Emerging Microbes and Infections</i> , 2022, 11, 250-259.	3.0	3
635	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
636	B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses. <i>Emerging Microbes and Infections</i> , 2022, 11, 452-464.	3.0	8
637	Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. <i>Science Advances</i> , 2022, 8, eabj9815.	4.7	29
639	SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection. <i>PLoS Pathogens</i> , 2022, 18, e1010242.	2.1	7

#	ARTICLE	IF	CITATIONS
641	Assessment of COVID-19 mRNA vaccination titer and side effects in healthy volunteers. <i>Laboratoriums Medizin</i> , 2022, 46, 107-114.	0.1	6
642	Glial fibrillary acidic protein astrocytopathy in a patient with recent mRNA SARS-CoV-2 vaccination. <i>Neuroimmunology Reports</i> , 2022, 2, 100053.	0.2	1
643	SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. <i>Cell Host and Microbe</i> , 2022, 30, 154-162.e5.	5.1	153
644	mRNA Vaccines in the COVID-19 Pandemic and Beyond. <i>Annual Review of Medicine</i> , 2022, 73, 17-39.	5.0	120
646	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1.	2.6	144
648	Rapid and sensitive identification of omicron by variant-specific PCR and nanopore sequencing: paradigm for diagnostics of emerging SARS-CoV-2 variants. <i>Medical Microbiology and Immunology</i> , 2022, 211, 71-77.	2.6	25
649	In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 2649-2655.	1.3	1
650	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	57
651	The Kinetics of COVID-19 Vaccine Response in a Community-Vaccinated Population. <i>Journal of Immunology</i> , 2022, 208, 819-826.	0.4	9
652	Structural biology of SARS-CoV-2: open the door for novel therapies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 26.	7.1	139
653	B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination. <i>Cell Reports</i> , 2022, 38, 110393.	2.9	29
654	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 490-495.	15.2	577
655	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
656	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. <i>Cell</i> , 2022, 185, 1008-1024.e15.	13.5	101
657	Accuracy and real life performance of a novel interferon- $\gamma$ release assay for the detection of SARS-CoV2 specific T cell response. <i>Journal of Clinical Virology</i> , 2022, 148, 105098.	1.6	24
658	SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 373-385.	1.1	24
659	Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 103, 115656.	0.8	8
660	BepiTBR: T-B reciprocity enhances B cell epitope prediction. <i>IScience</i> , 2022, 25, 103764.	1.9	9

#	ARTICLE	IF	CITATIONS
661	Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2. <i>Molecular Therapy</i> , 2022, 30, 1926-1940.	3.7	16
662	The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. <i>Journal of Infection and Public Health</i> , 2022, 15, 228-240.	1.9	122
663	A chitosan-mediated inhalable nanovaccine against SARS-CoV-2. <i>Nano Research</i> , 2022, 15, 4191-4200.	5.8	28
665	Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein. <i>Virus Research</i> , 2022, 310, 198674.	1.1	24
666	Phylogenetic analysis of SARS-CoV-2 viruses circulating in the South American region: Genetic relations and vaccine strain match. <i>Virus Research</i> , 2022, 311, 198688.	1.1	1
667	SARS-CoV-2 variant surge and vaccine breakthrough infection: A computational analysis. <i>Informatics in Medicine Unlocked</i> , 2022, 29, 100873.	1.9	1
669	In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105236.	1.0	6
670	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2022, 14, eabi9215.	5.8	123
671	The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. <i>Journal of Medical Virology</i> , 2022, 94, 2376-2383.	2.5	322
672	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals: EAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336.	2.7	12
673	The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. <i>Cell</i> , 2022, 185, 447-456.e11.	13.5	736
675	Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 23-31.	1.9	17
677	Socio-demographic Heterogeneity in Prevalence of SARS-COV-2 Infection and Death Rate: Relevance to Black College Student Knowledge of COVID-19 and SARS-COV-2. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022, , 1.	1.8	2
678	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	2.2	73
679	Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater. <i>Nature Communications</i> , 2022, 13, 635.	5.8	121
680	Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	26
681	Synthesis of siRNA nanoparticles to silence plaque-stabilizing gene in atherosclerotic lesional macrophages. <i>Nature Protocols</i> , 2022, 17, 748-780.	5.5	52
682	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248.	2.1	48

#	ARTICLE	IF	CITATIONS
683	A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 766821.	2.2	15
684	Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. <i>Infection</i> , 2022, 50, 309-325.	2.3	112
685	Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. <i>Cell Reports</i> , 2021, 37, 110156.	2.9	67
686	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 0, , .	13.7	104
687	The germinal centre B cell response to SARS-CoV-2. <i>Nature Reviews Immunology</i> , 2022, 22, 7-18.	10.6	150
688	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 2022, 602, 654-656.	13.7	928
689	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)â€™Specific Memory B Cells From Individuals With Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern. <i>Journal of Infectious Diseases</i> , 2022, 225, 947-956.	1.9	13
698	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , 2021, 374, 1621-1626.	6.0	232
700	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. <i>ELife</i> , 2021, 10, .	2.8	36
702	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2021, , eabj5305.	5.8	4
703	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2021, , eabm3302.	5.8	13
705	ChAdOx1 nCoV-19, BNT162b2 and CoronaVac Vaccines Do Not Induce as Strong Neutralising Antibodies with Broad Variant Protection as Infection and Suggest Vaccines that Induce Broader Sterilising Immunity are Essential to Stop the Pandemic. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
706	Predictive Model for Adverse Events and Immune Response Based on the Production of Antibodies After the Second-Dose of the BNT162b2 mRNA Vaccine. <i>Yonago Acta Medica</i> , 2022, 65, 63-69.	0.3	3
707	Probabilistic classification of antiâ€™SARSâ€™CoVâ€™2 antibody responses improves seroprevalence estimates. <i>Clinical and Translational Immunology</i> , 2022, 11, e1379.	1.7	4
708	COVID-19 infection and neurodegeneration: Computational evidence for interactions between the SARS-CoV-2 spike protein and monoamine oxidase enzymes. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1254-1263.	1.9	13
710	SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. <i>MBio</i> , 2022, 13, e0322721.	1.8	48
711	COVID-19 Vaccine: Between Myth and Truth. <i>Vaccines</i> , 2022, 10, 349.	2.1	12
712	Nonhuman Primates in Translational Research. <i>Annual Review of Animal Biosciences</i> , 2022, 10, 441-468.	3.6	11

#	ARTICLE	IF	CITATIONS
713	SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. <i>Science</i> , 2022, 375, 782-787.	6.0	60
714	Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 750-753.	1.2	11
715	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. <i>Scientific Reports</i> , 2022, 12, 2628.	1.6	34
717	Nanostructures for the Prevention, Diagnosis, and Treatment of SARS-CoV-2: A Review. <i>ACS Applied Nano Materials</i> , 2022, 5, 6029-6054.	2.4	12
718	Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 142.	2.4	24
719	Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. <i>Cell Research</i> , 2022, 32, 375-382.	5.7	21
720	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	73
721	Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. <i>Communications Biology</i> , 2022, 5, 169.	2.0	118
722	Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2. <i>BMC Immunology</i> , 2022, 23, 7.	0.9	6
723	Analysis of the Neutralizing Activity of Antibodies Targeting Open or Closed SARS-CoV-2 Spike Protein Conformations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2078.	1.8	5
724	Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan. <i>Vaccines</i> , 2022, 10, 312.	2.1	3
727	Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. <i>PLoS Pathogens</i> , 2022, 18, e1010260.	2.1	81
728	Innate Immune Response in SARS-CoV-2 Infection. <i>Microorganisms</i> , 2022, 10, 501.	1.6	13
729	SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. <i>Cell</i> , 2022, 185, 603-613.e15.	13.5	176
730	Cellular Immunityâ€™The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination. <i>Vaccines</i> , 2022, 10, 442.	2.1	21
731	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
732	Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile. <i>Microbiology Spectrum</i> , 2022, 10, e0273221.	1.2	35
733	Gauging the Impact of Artificial Intelligence and Mathematical Modeling in Response to the COVID-19 Pandemic: A Systematic Review. <i>BioMed Research International</i> , 2022, 2022, 1-28.	0.9	7

#	ARTICLE	IF	CITATIONS
734	The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals. <i>Vaccine</i> , 2022, 40, 1928-1931.	1.7	5
735	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. <i>Cell Reports</i> , 2022, 38, 110561.	2.9	16
738	Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, 845887.	2.2	13
739	E-Volve: understanding the impact of mutations in SARS-CoV-2 variants spike protein on antibodies and ACE2 affinity through patterns of chemical interactions at protein interfaces. <i>PeerJ</i> , 2022, 10, e13099.	0.9	3
740	Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape. <i>MBio</i> , 2022, 13, e0013522.	1.8	35
741	Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination. <i>Science</i> , 2022, 375, 1041-1047.	6.0	59
743	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. <i>ACS Infectious Diseases</i> , 2022, 8, 825-840.	1.8	3
744	Targeted Sanger sequencing to recover key mutations in SARS-CoV-2 variant genome assemblies produced by next-generation sequencing. <i>Microbial Genomics</i> , 2022, 8, .	1.0	7
745	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
746	Structural basis of nanobodies neutralizing SARS-CoV-2 variants. <i>Structure</i> , 2022, 30, 707-720.e5.	1.6	11
747	Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions. <i>IScience</i> , 2022, 25, 103939.	1.9	32
748	Antigen-Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 797132.	1.6	3
749	Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. <i>Science Translational Medicine</i> , 2022, 14, eabm3410.	5.8	49
750	IgM responses following SARS-CoV-2 vaccination: insights into protective and pre-existing immunity. <i>EBioMedicine</i> , 2022, 77, 103922.	2.7	7
751	Clinical Features and Time to Recovery of Admitted COVID-19 Cases at Dilla University Referral Hospital Treatment Center, South Ethiopia. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 795-806.	1.1	5
752	Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. <i>ELife</i> , 2022, 11, .	2.8	34
753	Tracking SARS-CoV-2 Mutations & Variants Through the COG-UK-Mutation Explorer. <i>Virus Evolution</i> , 2022, 8, veac023.	2.2	19
754	Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. <i>JAMA Oncology</i> , 2022, 8, e220446.	3.4	48

#	ARTICLE	IF	CITATIONS
755	Rapid and parallel adaptive mutations in spike S1 drive clade success in SARS-CoV-2. <i>Cell Host and Microbe</i> , 2022, 30, 545-555.e4.	5.1	59
756	Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. <i>Scientific Reports</i> , 2022, 12, 3788.	1.6	22
758	Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. <i>Frontiers in Immunology</i> , 2022, 13, 773982.	2.2	10
759	A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	49
760	Injectable Slow-Release Hydrogel Formulation of a Plant Virus-Based COVID-19 Vaccine Candidate. <i>Biomacromolecules</i> , 2022, 23, 1812-1825.	2.6	20
761	Neutralizing Antibodies and Cellular Immune Responses Against SARS-CoV-2 Sustained One and a Half Years After Natural Infection. <i>Frontiers in Microbiology</i> , 2021, 12, 803031.	1.5	18
762	Study of humoral and cellular immunity in vaccinated with mRNA. <i>Apms</i> , 2022, 130, 261-269.	0.9	3
763	An extended conformation of SARS-CoV-2 main protease reveals allosteric targets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120913119.	3.3	20
765	Circular RNA vaccines against SARS-CoV-2 and emerging variants. <i>Cell</i> , 2022, 185, 1728-1744.e16.	13.5	211
766	SARS-CoV-2 variants and vulnerability at the global level. <i>Journal of Medical Virology</i> , 2022, 94, 2986-3005.	2.5	79
767	Identifying vaccine escape sites via statistical comparisons of short-term molecular dynamics. <i>Biophysical Reports</i> , 2022, 2, 100056.	0.7	2
768	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1133-1157.	0.8	22
770	A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 114.	7.1	17
771	Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 834942.	2.2	10
773	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104043.	1.9	19
774	Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. <i>Immunity</i> , 2022, 55, 1096-1104.e4.	6.6	42
775	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. <i>Immunity</i> , 2022, 55, 998-1012.e8.	6.6	86
777	There is nothing exempt from the peril of mutation – The Omicron spike. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112756.	2.5	11



#	ARTICLE	IF	CITATIONS
778	Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2. <i>Molecular Biology Reports</i> , 2022, 49, 4061-4068.	1.0	5
779	Landscape-Based Protein Stability Analysis and Network Modeling of Multiple Conformational States of the SARS-CoV-2 Spike D614G Mutant: Conformational Plasticity and Frustration-Induced Allosterism as Energetic Drivers of Highly Transmissible Spike Variants. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 1956-1978.	2.5	5
780	Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2 infected and spike-transfected cells and mediate NK cell degranulation. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, . . .	1.1	4
781	The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. <i>International Journal of Biological Macromolecules</i> , 2022, 208, 105-125.	3.6	41
782	Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. <i>Microbiological Research</i> , 2022, 258, 126993.	2.5	22
783	mRNA vaccines for COVID-19 and diverse diseases. <i>Journal of Controlled Release</i> , 2022, 345, 314-333.	4.8	50
784	COVID-19 mRNA Based Vaccine Immune-Response Assessment in Nursing Home Residents for Public Health Decision. <i>Vaccines</i> , 2021, 9, 1429.	2.1	4
787	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003868.	3.9	20
789	Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors. <i>Cell and Bioscience</i> , 2021, 11, 199.	2.1	26
790	Plasmonically Enhanced Ultrasensitive Epitope-Specific Serologic Assay for COVID-19. <i>Analytical Chemistry</i> , 2022, 94, 909-917.	3.2	6
791	Capturing adaptive immunity against SARS-CoV-2 in patients with cancer. <i>Nature Cancer</i> , 2021, 2, 1298-1300.	5.7	2
794	Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization. <i>Viruses</i> , 2021, 13, 2440.	1.5	8
795	The atomic portrait of SARS-CoV-2 as captured by cryo-electron microscopy. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 25-34.	1.6	6
796	Comparison of SARS-CoV-2-Specific Antibodies in Human Milk after mRNA-Based COVID-19 Vaccination and Infection. <i>Vaccines</i> , 2021, 9, 1475.	2.1	13
800	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
803	COVID-19 Vaccination: The Mainspring of Challenges and the Seed of Remonstrance. <i>Vaccines</i> , 2021, 9, 1474.	2.1	6
804	Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population. <i>Vaccines</i> , 2021, 9, 1494.	2.1	9
806	Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 795741.	2.2	13

#	ARTICLE	IF	CITATIONS
807	Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens. <i>PLoS Pathogens</i> , 2021, 17, e1010085.	2.1	13
808	Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine. <i>Journal of Medical Virology</i> , 2022, 94, 1566-1580.	2.5	26
809	Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time. <i>Clinical and Translational Immunology</i> , 2022, 11, e1388.	1.7	20
810	mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. <i>Science Translational Medicine</i> , 2022, 14, eabm2311.	5.8	100
811	A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques. <i>Frontiers in Immunology</i> , 2022, 13, 857440.	2.2	15
812	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. <i>Cell Reports</i> , 2022, 39, 110757.	2.9	10
813	Mutational Effect of Some Major COVID-19 Variants on Binding of the S Protein to ACE2. <i>Biomolecules</i> , 2022, 12, 572.	1.8	8
814	T cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity. <i>JCI Insight</i> , 2022, 7, .	2.3	26
815	Structures of Omicron spike complexes and implications for neutralizing antibody development. <i>Cell Reports</i> , 2022, 39, 110770.	2.9	47
816	Investigations on SARS-CoV-2 Susceptibility of Domestic and Wild Animals Using Primary Cell Culture Models Derived from the Upper and Lower Respiratory Tract. <i>Viruses</i> , 2022, 14, 828.	1.5	10
817	Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis. <i>Scientific Reports</i> , 2022, 12, 6241.	1.6	12
818	mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2. <i>Med</i> , 2022, 3, 309-324.e6.	2.2	6
819	BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 797918.	2.2	1
820	COVID-19: A Systematic Review of the Transmissibility, Pathogenesis, Entry Factors, and Signature Immune Response. <i>Biochem</i> , 2022, 2, 115-144.	0.5	1
821	An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. <i>Science Translational Medicine</i> , 2022, 14, eabn6859.	5.8	31
822	Reproduction Number of the Omicron Variant Triples That of the Delta Variant. <i>Viruses</i> , 2022, 14, 821.	1.5	38
823	Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	14
824	Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. <i>Communications Medicine</i> , 2022, 2, .	1.9	32

#	ARTICLE	IF	CITATIONS
825	Development of antibody resistance in emerging mutant strains of SARS-CoV-2: Impediment for COVID-19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
826	A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity. <i>Molecular Therapy</i> , 2022, 30, 2968-2983.	3.7	20
827	Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients. <i>European Journal of Immunology</i> , 2022, 52, 1297-1307.	1.6	37
829	Repurposing of Four Drugs as Anti-SARS-CoV-2 Agents and Their Interactions with Protein Targets. <i>Scientia Pharmaceutica</i> , 2022, 90, 24.	0.7	7
830	Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity. <i>Viruses</i> , 2022, 14, 803.	1.5	10
831	Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection. <i>JCI Insight</i> , 2022, 7, .	2.3	15
832	SARS-CoV-2 IgM testing for travellers: a private pathology perspective from New South Wales and the Australian Capital Territory, Australia. <i>Pathology</i> , 2022, , .	0.3	0
833	Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2. <i>Nature Communications</i> , 2022, 13, 2237.	5.8	27
834	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. <i>Nature</i> , 2022, 607, 128-134.	13.7	197
835	Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain. <i>MBio</i> , 2022, 13, e0358021.	1.8	12
836	Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2212-2222.	1.9	4
837	Broadly neutralizing antibodies against SARS-CoV-2 variants. , 2022, 1, 20220005.		3
838	Clinical challenges of SARS-CoV-2 variants (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 23, .	0.8	12
839	Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2624-2639.	5.7	30
840	Dual-Positive MPO- and PR3-ANCA-Associated Vasculitis Following SARS-CoV-2 mRNA Booster Vaccination: A Case Report and Systematic Review. <i>Vaccines</i> , 2022, 10, 653.	2.1	21
841	2'- and 3'-Ribose Modifications of Nucleotide Analogues Establish the Structural Basis to Inhibit the Viral Replication of SARS-CoV-2. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 4111-4118.	2.1	11
842	Comprehensive role of SARS-CoV-2 spike glycoprotein in regulating host signaling pathway. <i>Journal of Medical Virology</i> , 2022, 94, 4071-4087.	2.5	5
843	Mutations in spike protein T cell epitopes of SARS-COV-2 variants: Plausible influence on vaccine efficacy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166432.	1.8	8

#	ARTICLE	IF	CITATIONS
844	Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection. <i>Biochemistry</i> , 2022, 61, 963-980.	1.2	12
845	Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants. <i>MAbs</i> , 2022, 14, 2072455.	2.6	9
846	Whole genome sequencing of SARS-CoV2 strains circulating in Iran during five waves of pandemic. <i>PLoS ONE</i> , 2022, 17, e0267847.	1.1	20
847	Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients. <i>Communications Biology</i> , 2022, 5, 409.	2.0	5
848	Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host. <i>Nature Communications</i> , 2022, 13, 2560.	5.8	64
849	Adaptive Immune Responses and Immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	39
850	Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection. <i>Science Immunology</i> , 2022, 7, eabq3511.	5.6	82
851	COVID-19 vaccination challenges: A mini-review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	1.4	5
852	Recent trends in next generation immunoinformatics harnessed for universal coronavirus vaccine design. <i>Pathogens and Global Health</i> , 2023, 117, 134-151.	1.0	2
853	nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination. <i>Dr Sulaiman Al Habib Medical Journal</i> , 0, , 1.	0.3	0
854	Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern. <i>Virology</i> , 2022, 572, 44-54.	1.1	21
855	Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants. <i>EBioMedicine</i> , 2022, 80, 104025.	2.7	13
856	Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study. <i>Computers in Biology and Medicine</i> , 2022, 146, 105552.	3.9	16
857	Equipment-free, gold nanoparticle based semiquantitative assay of SARS-CoV-2-S1RBD IgG from fingertip blood: A practical strategy for on-site measurement of COVID-19 antibodies. <i>Talanta</i> , 2022, 246, 123498.	2.9	3
858	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
859	Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccination. <i>JCI Insight</i> , 2022, 7, .	2.3	13
860	Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	1.8	6
861	Bioinformatics for the Origin and Evolution of Viruses. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1368, 53-71.	0.8	2

#	ARTICLE	IF	CITATIONS
862	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. <i>Indian Journal of Medical Research</i> , 2022, 155, 105.	0.4	2
863	Antibody repertoire sequencing analysis. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, , .	0.9	2
864	Understanding "Hybrid Immunity" Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. <i>Clinical Infectious Diseases</i> , 2023, 76, e439-e449.	2.9	23
865	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. <i>Cell</i> , 2022, 185, 2116-2131.e18.	13.5	105
866	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	43
867	Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England. <i>Epidemiology and Infection</i> , 2022, 150, .	1.0	8
868	Identifying COVID-19 Severity-Related SARS-CoV-2 Mutation Using a Machine Learning Method. <i>Life</i> , 2022, 12, 806.	1.1	11
870	Protective neutralizing epitopes in SARS-CoV-2. <i>Immunological Reviews</i> , 2022, 310, 76-92.	2.8	23
871	Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 81.	0.9	15
872	Real-time allelic assays of SARS-CoV-2 variants to enhance sewage surveillance. <i>Water Research</i> , 2022, 220, 118686.	5.3	17
873	An early warning system for emerging SARS-CoV-2 variants. <i>Nature Medicine</i> , 2022, 28, 1110-1115.	15.2	47
875	The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination. <i>Vaccines</i> , 2022, 10, 794.	2.1	5
876	Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	25
877	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. <i>PLoS ONE</i> , 2022, 17, e0268767.	1.1	18
878	COVID-19 outcomes in immunocompromised individuals: seroconversion and vaccine effectiveness. <i>LymphoSign Journal</i> , 0, , .	0.1	1
879	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis. <i>Lancet Microbe</i> , The, 2022, 3, e493-e502.	3.4	22
880	Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	24
881	Two Separate Clusters of SARS-CoV-2 Delta Variant Infections in a Group of 41 Students Travelling from India: An Illustration of the Need for Rigorous Testing and Quarantine. <i>Viruses</i> , 2022, 14, 1198.	1.5	4

#	ARTICLE	IF	CITATIONS
882	Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 64, 103937.	0.9	18
883	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. <i>Nature Immunology</i> , 2022, 23, 960-970.	7.0	39
885	Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) Serology in the Vaccination Era and Post Booster Vaccination. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
886	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 173.	1.1	0
887	Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination. <i>Vaccines</i> , 2022, 10, 874.	2.1	5
889	Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review. <i>Vaccines</i> , 2022, 10, 909.	2.1	6
890	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
891	Investigation of Antibody Levels During Three Doses of Sinopharm/BBIBP Vaccine Inoculation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
892	High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium. <i>Viruses</i> , 2022, 14, 1257.	1.5	7
893	Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history. <i>Genome Medicine</i> , 2022, 14, .	3.6	15
894	Statistics of antibody binding to the spike protein explain the dependence of COVID 19 infection risk on antibody concentration and affinity. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
896	Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	5
898	Safety and efficacy of coronavirus diseaseâ€”19 vaccines in chronic kidney disease patients under maintenance hemodialysis: A systematic review. <i>Health Science Reports</i> , 2022, 5, .	0.6	8
899	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	28
900	Rapid and accurate identification of SARS-CoV-2 Omicron variants using droplet digital PCR (RT-ddPCR). <i>Journal of Clinical Virology</i> , 2022, 154, 105218.	1.6	12
901	COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases. <i>Journal of Autoimmunity</i> , 2022, 131, 102846.	3.0	6
902	The uptake of metalâ€”organic frameworks: a journey into the cell. <i>Chemical Society Reviews</i> , 2022, 51, 6065-6086.	18.7	55
903	Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes. <i>Journal of Virology</i> , 2022, 96, .	1.5	10

#	ARTICLE	IF	CITATIONS
904	An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry. <i>Emerging Microbes and Infections</i> , 2022, 11, 1920-1935.	3.0	7
905	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
906	Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	38
907	Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 1004-1013.	1.5	7
908	Anti-membrane Antibodies Persist at Least One Year and Discriminate Between Past Coronavirus Disease 2019 Infection and Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 1897-1902.	1.9	9
909	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
910	Evaluation of lymphocyte count, T-cell subsets and neutrophil-to-lymphocyte ratio as early predictors for severity and outcome of COVID-19 disease—a report from a highly complex hospital in Brazil. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, , .	0.1	3
911	The humoral response and antibodies against SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 1008-1020.	7.0	84
912	Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease. <i>Vaccines</i> , 2022, 10, 1036.	2.1	2
913	Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture. <i>Communications Biology</i> , 2022, 5, .	2.0	6
914	SARS-CoV-2 Vaccines: The Mucosal Immunity Imperative. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1771-1773.	1.4	6
915	Monoclonal antibody therapies against SARS-CoV-2. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e311-e326.	4.6	114
917	Two Years of Evolutionary Dynamics of SARS-CoV-2 in Mexico, With Emphasis on the Variants of Concern. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
918	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	10
919	Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 5707-5727.	2.0	7
920	SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. <i>Nature Microbiology</i> , 2022, 7, 1161-1179.	5.9	352
921	The global mRNA vaccine patent landscape. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	4
922	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6

#	ARTICLE	IF	CITATIONS
923	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. Immunological Reviews, 2022, 309, 40-63.	2.8	26
924	Guardians of the oral and nasopharyngeal galaxy: <scp>IgA</scp> and protection against <scp>SARSâ€CoV</scp>â€2 infection*. Immunological Reviews, 2022, 309, 75-85.	2.8	32
925	Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity. Obesity Surgery, 2022, 32, 2987-2993.	1.1	14
926	Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science, 2022, 377, .	6.0	120
927	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. IScience, 2022, 25, 104705.	1.9	8
928	Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study. Multiple Sclerosis and Related Disorders, 2022, 65, 104009.	0.9	3
929	Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys. Nature Microbiology, 2022, 7, 1376-1389.	5.9	33
930	Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Science Immunology, 2022, 7, .	5.6	170
931	Sequence similarity of SARS-CoV-2 and humans: Implications for SARS-CoV-2 detection. Frontiers in Genetics, 0, 13, .	1.1	2
932	Effectiveness of ComirnatyÂ® Vaccine and Correlates of Immunogenicity and Adverse Reactions: A Single-Center Prospective Case Series Study. Vaccines, 2022, 10, 1170.	2.1	2
933	Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD. International Journal of Molecular Sciences, 2022, 23, 8177.	1.8	5
935	Nanomechanical analysis of SARS-CoV-2 variants and predictions of infectiousness and lethality. Soft Matter, 2022, 18, 5833-5842.	1.2	3
936	Seroprevalence Surgery of Anti-SARS-CoV-2 Antibodies Based on COVID-19 Vaccine Type in Academy Community, East Kalimantan, Indonesia. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 1169-1173.	0.1	0
938	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. International Journal of Molecular Sciences, 2022, 23, 8485.	1.8	6
939	Macrotrponin Complex as a Cause for Cardiac Troponin Increase after COVID-19 Vaccination and Infection. Clinical Chemistry, 2022, 68, 1015-1019.	1.5	8
940	Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2. Frontiers in Immunology, 0, 13, .	2.2	3
941	Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron. Communications Biology, 2022, 5, .	2.0	9
942	Understanding the Excitation Wavelength Dependence and Thermal Stability of the SARS-CoV-2 Receptor-Binding Domain Using Surface-Enhanced Raman Scattering and Machine Learning. ACS Photonics, 2022, 9, 2963-2972.	3.2	10



#	ARTICLE	IF	CITATIONS
943	Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21
944	Effects of Covid-19 vaccination on different semen parameters. <i>Basic and Clinical Andrology</i> , 2022, 32, .	0.8	13
946	A Rapid and Sensitive Microfluidics-Based Tool for Seroprevalence Immunity Assessment of COVID-19 and Vaccination-Induced Humoral Antibody Response at the Point of Care. <i>Biosensors</i> , 2022, 12, 621.	2.3	7
947	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
948	Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort. <i>Viruses</i> , 2022, 14, 1766.	1.5	13
949	mRNA vaccines in the prevention and treatment of diseases. <i>MedComm</i> , 2022, 3, .	3.1	14
950	Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses. <i>Immunity</i> , 2022, 55, 1856-1871.e6.	6.6	54
951	COVID-19 Vaccine Clinical Trials: A Bird's Eye Perspective. <i>Cureus</i> , 2022, , .	0.2	0
953	Within-host dynamics of SARS-CoV-2 infection: A systematic review and meta-analysis. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 3964-3971.	1.3	5
954	Molecular Dynamics Analysis of Fast-Spreading Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Their Effects on the Interaction with Human Angiotensin-Converting Enzyme 2. <i>ACS Omega</i> , 2022, 7, 30700-30709.	1.6	6
956	A key F27I substitution within HCDR1 facilitates the rapid maturation of P2C-1F11-like neutralizing antibodies in a SARS-CoV-2-infected donor. <i>Cell Reports</i> , 2022, 40, 111335.	2.9	2
957	Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	12
958	Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants. <i>Journal of Clinical Immunology</i> , 2023, 43, 31-45.	2.0	4
959	Potential Coronaviral Inhibitors of the Nucleocapsid Protein Identified In Silico and In Vitro from a Large Natural Product Library. <i>Pharmaceuticals</i> , 2022, 15, 1046.	1.7	2
960	Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	9
963	Nutrition as Personalized Medicine against SARS-CoV-2 Infections: Clinical and Oncological Options with a Specific Female Groups Overview. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9136.	1.8	17
964	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	15
965	Delta SARS-CoV-2 inactivation and bactericidal performance of cotton wipes decorated with TiO <sub>2</sub> /Ag nanoparticles like Brazilian heavy-fruited <i>Myrciaria cauliflora</i> . <i>Materials Today Communications</i> , 2022, 33, 104288.	0.9	3

#	ARTICLE	IF	CITATIONS
966	Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COVS SARS-CoV-2 vaccines in healthcare workers. <i>International Journal of Infectious Diseases</i> , 2022, 123, 183-191.	1.5	8
967	Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. <i>Biomedical Engineering Advances</i> , 2022, 4, 100054.	2.2	3
968	Protein A/G-based surface plasmon resonance biosensor for regenerable antibody-mediated capture and analysis of nanoparticles. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2022, 654, 130015.	2.3	7
969	Preparation of methacrylated hyaluronate/methacrylated collagen sponges with rapid shape recovery and orderly channel for fast blood absorption as hemostatic dressing. <i>International Journal of Biological Macromolecules</i> , 2022, 222, 30-40.	3.6	9
970	Emergence of COVID-19 Variants and Its Global Impact. , 2022, , 183-201.		1
971	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
972	Antibody levels over time against the novel coronavirus and incidence of adverse reaction after vaccination. <i>Health Evaluation and Promotion</i> , 2022, 49, 462-469.	0.0	0
973	Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
974	Vaccine-Associated Uveitis after COVID-19 Vaccination. <i>Ophthalmology</i> , 2023, 130, 179-186.	2.5	25
975	Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation. <i>Viruses</i> , 2022, 14, 1916.	1.5	7
976	The role of B cells in COVID-19 infection and vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	25
977	Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants. <i>PLoS Computational Biology</i> , 2022, 18, e1010563.	1.5	4
978	Lymphocyte Subpopulations Associated with Neutralizing Antibody Levels of SARS-CoV-2 for COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1550.	2.1	4
979	Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	37
980	An ACE2-dependent Sarbecovirus in Russian bats is resistant to SARS-CoV-2 vaccines. <i>PLoS Pathogens</i> , 2022, 18, e1010828.	2.1	25
983	The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	71
984	Production of two SARS-CoV-2 neutralizing antibodies with different potencies in <i>Nicotiana benthamiana</i> . <i>Frontiers in Plant Science</i> , 0, 13, .	1.7	4
985	Immune responses to SARS-CoV-2 infection and COVID-19 vaccines. <i>Exploration of Immunology</i> , 2022, 2, 648-664.	1.7	1

#	ARTICLE	IF	CITATIONS
986	Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. <i>Science Advances</i> , 2022, 8, .	4.7	22
987	An Update on Complications Associated with SARS-CoV-2 Infection and COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1639.	2.1	1
989	A retrospective analysis of respiratory virus transmission before and during the COVID-19 pandemic in Pune the western region of India. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	4
990	Dynamics of B-Cell Responses after SARS-CoV-2 Vaccination in Spain. <i>Vaccines</i> , 2022, 10, 1615.	2.1	2
991	SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope. <i>Nature Microbiology</i> , 2022, 7, 1635-1649.	5.9	25
993	Localized delivery of nanomedicine and antibodies for combating COVID-19. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1828-1846.	5.7	5
994	SARS-CoV-2 in immunocompromised individuals. <i>Immunity</i> , 2022, 55, 1779-1798.	6.6	50
995	COVID-19 and cellular senescence. <i>Nature Reviews Immunology</i> , 2023, 23, 251-263.	10.6	54
996	Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2023, 76, 201-209.	2.9	10
997	Tissue resident memory T cells- A new benchmark for the induction of vaccine-induced mucosal immunity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
999	Dynamics of SARS-CoV-2 lineages in French Guiana in 2020â€“2021: 4 epidemic waves with cross-influences from Europe and South America. <i>Infection, Genetics and Evolution</i> , 2022, 105, 105370.	1.0	1
1000	Monkeypox virus: An emerging epidemic. <i>Microbial Pathogenesis</i> , 2022, 173, 105794.	1.3	22
1002	SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations. <i>Cell Reports</i> , 2022, 41, 111496.	2.9	20
1004	Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination. <i>Vaccines</i> , 2022, 10, 1784.	2.1	1
1005	Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 2749-2761.	3.0	9
1006	Assessing T-Cell Immunity in Kidney Transplant Recipients with Absent Antibody Production after a 3rd Dose of the mRNA-1273 Vaccine. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12333.	1.8	4
1007	Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0263861.	1.1	12
1008	The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection. <i>Vaccines</i> , 2022, 10, 1699.	2.1	15

#	ARTICLE	IF	CITATIONS
1009	A comprehensive update on CIDO: the community-based coronavirus infectious disease ontology. <i>Journal of Biomedical Semantics</i> , 2022, 13, .	0.9	7
1010	HIV skews the SARS-CoV-2 B cell response towards an extrafollicular maturation pathway. <i>ELife</i> , 0, 11, .	2.8	6
1011	Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation. <i>Chemico-Biological Interactions</i> , 2022, 368, 110244.	1.7	4
1013	Development and characterization of a new monoclonal antibody against SARS-CoV-2 NSP12 (RdRp). <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
1014	A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database. <i>Human Vaccines and Immunotherapeutics</i> , 0, , .	1.4	2
1015	Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination. <i>IScience</i> , 2022, 25, 105379.	1.9	4
1016	SARS-CoV-2 Omicron (BA.1 and BA.2) specific novel CD8+ and CD4+ T cell epitopes targeting spike protein. <i>Immunoinformatics</i> , 2022, 8, 100020.	1.2	2
1018	Subgenomic RNAs and Their Encoded Proteins Contribute to the Rapid Duplication of SARS-CoV-2 and COVID-19 Progression. <i>Biomolecules</i> , 2022, 12, 1680.	1.8	0
1019	Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination. <i>Journal of Clinical Virology Plus</i> , 2023, 3, 100130.	0.4	0
1020	Protection against SARS-CoV-2 BA.4 and BA.5 subvariants via vaccination and natural infection: A modeling study. <i>Mathematical Biosciences and Engineering</i> , 2022, 20, 2530-2543.	1.0	1
1021	SARS-COV-2: INSIGHT INTO THE EMERGING GENETIC VARIANTS. , 2022, 49, 5-11.		0
1023	High throughput bioluminescent assay to characterize and monitor the activity of SARS-CoV-2 methyltransferases. <i>PLoS ONE</i> , 2022, 17, e0274343.	1.1	0
1024	SARS-CoV-2 epitopes inform future vaccination strategies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1025	Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. <i>Science China Life Sciences</i> , 2023, 66, 658-678.	2.3	3
1026	SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy. <i>Biomolecules</i> , 2022, 12, 1742.	1.8	6
1027	Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
1028	SARS-CoV-2 antibody response to third dose vaccination in a healthy cohort. <i>Insights in Clinical and Cellular Immunology</i> , 2022, 6, 008-013.	0.1	1
1029	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6

#	ARTICLE	IF	CITATIONS
1030	Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
1031	Challenges and developments in universal vaccine design against SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, .	2.9	25
1032	Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. <i>Nature</i> , 2023, 613, 735-742.	13.7	38
1034	An Evaluation of Serological Tests to Determine Postvaccinal Immunity to SARS-CoV-2 by mRNA Vaccines. <i>Journal of Clinical Medicine</i> , 2022, 11, 7534.	1.0	0
1036	A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets. <i>Science Advances</i> , 2022, 8, .	4.7	12
1037	Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern. <i>Npj Vaccines</i> , 2022, 7, .	2.9	9
1038	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. <i>Nature Communications</i> , 2022, 13, .	5.8	17
1039	Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines. <i>International Immunology</i> , 2023, 35, 213-220.	1.8	6
1040	Neutralizing and enhancing antibodies against SARS-CoV-2. <i>Inflammation and Regeneration</i> , 2022, 42, .	1.5	6
1041	Vaccine-associated corneal graft rejection following SARS-CoV-2 vaccination: a CDC-VAERS database analysis. <i>British Journal of Ophthalmology</i> , 2024, 108, 17-22.	2.1	4
1042	Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. <i>Scientific Reports</i> , 2022, 12, .	1.6	20
1043	Isolation and characterization of a SARS-CoV-2 variant with a Q677H mutation in the spike protein. <i>Archives of Virology</i> , 2023, 168, .	0.9	1
1044	Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	11
1045	Genomic Tracking of SARS-CoV-2 Variants in Myanmar. <i>Vaccines</i> , 2023, 11, 6.	2.1	0
1047	COVID-19 and Autoimmunity. , 2022, , 57-84.		0
1048	The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19. <i>Journal of Inflammation Research</i> , 0, Volume 16, 145-160.	1.6	5
1049	Bioinformatical Design and Performance Evaluation of a Nucleocapsid- and an RBD-Based Particle Enhanced Turbidimetric Immunoassay (PETIA) to Quantify the Wild Type and Variants of Concern-Derived Immunoreactivity of SARS-CoV-2. <i>Biomedicines</i> , 2023, 11, 160.	1.4	1
1050	Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
1051	mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	32
1052	Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants. <i>Cell Reports</i> , 2023, 42, 111995.	2.9	12
1053	Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5. <i>Cell Discovery</i> , 2023, 9, .	3.1	11
1055	A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 4291-4304.	5.7	2
1057	Functional heterogeneity in the memory B-cell response. <i>Current Opinion in Immunology</i> , 2023, 80, 102281.	2.4	0
1058	Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development. <i>Life Sciences</i> , 2023, 315, 121374.	2.0	3
1059	Scales, Pseudoscales, the Human Factor, and a Way Forward. , 2023, , 177-224.		0
1060	SARS-CoV-2 infection history and antibody response to three COVID-19 mRNA vaccine doses. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	2
1061	Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis. <i>Cornea</i> , 2023, 42, 731-738.	0.9	4
1062	A covalent opsonization approach to enhance synthetic immunity against viral escape variants. <i>Cell Reports Physical Science</i> , 2023, , 101258.	2.8	1
1063	Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails. <i>Acta Pharmacologica Sinica</i> , 0, , .	2.8	1
1064	Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines. <i>Trends in Molecular Medicine</i> , 2023, 29, 255-267.	3.5	17
1065	Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	14
1066	A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529). <i>International Journal of Nanomedicine</i> , 0, Volume 18, 353-367.	3.3	10
1067	Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi. <i>Vaccines</i> , 2023, 11, 299.	2.1	5
1068	Coronavirus Immunotherapeutic Consortium Database. <i>Database: the Journal of Biological Databases and Curation</i> , 2023, 2023, .	1.4	4
1069	Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape. <i>Nature Communications</i> , 2023, 14, .	5.8	21
1071	Impact of antibody-level on viral shedding in B.1.617.2 (Delta) variant-infected patients analyzed using a joint model of longitudinal and time-to-event data. <i>Mathematical Biosciences and Engineering</i> , 2023, 20, 8875-8891.	1.0	0

#	ARTICLE	IF	CITATIONS
1074	Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1075	COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease. <i>Drug Discovery Today</i> , 2023, 28, 103579.	3.2	22
1076	The Vaccines Induced Autoimmunity. , 2022, , 19-55.		0
1077	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
1078	Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1080	Angiotensin-converting enzyme 2 at the heart of the COVID-19 pandemic. <i>Cell</i> , 2023, 186, 906-922.	13.5	36
1081	Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic. <i>Genes</i> , 2023, 14, 407.	1.0	10
1082	A Protein Co-Conservation Network Model Characterizes Mutation Effects on SARS-CoV-2 Spike Protein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3255.	1.8	4
1084	Editorial: Innate immune responses to SARS-CoV-2 in infected and vaccinated individuals. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1085	Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals. <i>PLoS ONE</i> , 2023, 18, e0281689.	1.1	8
1086	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. <i>Immunity</i> , 2023, 56, 669-686.e7.	6.6	43
1087	Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	8
1088	Virus-like Particles of Nodavirus Displaying the Receptor Binding Domain of SARS-CoV-2 Spike Protein: A Potential VLP-Based COVID-19 Vaccine. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4398.	1.8	0
1089	B cell receptor repertoire analysis from autopsy samples of COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1090	Modeling and predicting the overlap of B- and T-cell receptor repertoires in healthy and SARS-CoV-2 infected individuals. <i>PLoS Genetics</i> , 2023, 19, e1010652.	1.5	7
1091	Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	0
1093	Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	4
1094	Variants of SARS-CoV-2: Influences on the Vaccines™ Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5

#	ARTICLE	IF	CITATIONS
1095	A novel mAb broadly neutralizes SARS-CoV-2 VOCs in vitro and in vivo, including the Omicron variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
1096	Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants. <i>Nature Immunology</i> , 2023, 24, 690-699.	7.0	16
1097	Pseudotyped Viruses for Coronaviruses. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 133-151.	0.8	0
1098	From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis. <i>Communications Biology</i> , 2023, 6, .	2.0	3
1099	mRNA Vaccines against SARS-CoV-2: Advantages and Caveats. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5944.	1.8	12
1101	SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies. <i>Npj Vaccines</i> , 2023, 8, .	2.9	3
1102	Tracking B Cell Memory to SARS-CoV-2 Using Rare Cell Analysis System. <i>Vaccines</i> , 2023, 11, 735.	2.1	0
1103	Aerosol transmission in queuing and dining scenarios in canteens and the effectiveness of control measures. <i>Journal of Building Performance Simulation</i> , 2023, 16, 660-679.	1.0	1
1104	Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review. <i>Cureus</i> , 2023, , .	0.2	1
1105	Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. <i>Viruses</i> , 2023, 15, 856.	1.5	10
1106	Anti-COVID-19 Credentials of Chitosan Composites and Derivatives: Future Scope?. <i>Antibiotics</i> , 2023, 12, 665.	1.5	1
1107	Travel history among persons infected with SARS-CoV-2 variants of concern in the United States, December 2020â€”February 2021. <i>PLOS Global Public Health</i> , 2023, 3, e0001252.	0.5	0
1109	HLA Variation and SARS-CoV-2 Specific Antibody Response. <i>Viruses</i> , 2023, 15, 906.	1.5	4
1110	SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. <i>Nature</i> , 2023, 617, 592-598.	13.7	49
1111	Implications of potential clinically relevant interactions between COVID-19 vaccines and concomitant medications. <i>Reviews in Medical Virology</i> , 0, , .	3.9	0
1114	The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: A genomics-based retrospective cohort analysis. <i>PLoS ONE</i> , 2023, 18, e0284187.	1.1	1
1115	Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. <i>Nature Communications</i> , 2023, 14, .	5.8	12
1116	Prediction of Post-Acute-Sequelae of COVID-19 by Cargo Protein Biomarkers of Blood Total Extracellular Vesicles in Acute COVID-19. <i>American Journal of Medicine</i> , 2023, 136, 824-829.	0.6	5



#	ARTICLE	IF	CITATIONS
1124	The Dawn of Microbiology. , 2023, , 17-26.		0
1148	Memory B cells. Nature Reviews Immunology, 2024, 24, 5-17.	10.6	13
1173	In Silico Analysis of Ferrocenyl-Analogs as the Potential Drugs Against Aggressive UK-Based Strain of SARS-CoV-2 Novel Coronavirus. Springer Proceedings in Materials, 2023, , 229-234.	0.1	0
1188	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4